Danthron | CAS#117-10-2 | HO-1/CPR BRET signal inhibitor

Danthron
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562160

CAS#: 117-10-2

Description: Danthron, also known as Chrysazine, Chrysazin, Dantron, and Antrapurol, is an inhibitor of HO-1/CPR BRET signal. It acts by significantly reducing BRETmax from cells coexpressing CPR-GFP and Luc-HO-1.

Chemical Structure

Danthron

CAS# 117-10-2

Instruction

Theoretical Analysis

MedKoo Cat#: 562160
Name: Danthron
CAS#: 117-10-2
Chemical Formula: C14H8O4
Exact Mass: 240.04
Molecular Weight: 240.210
Elemental Analysis: C, 70.00; H, 3.36; O, 26.64

Price and Availability

Size	Price	Availability	Quantity
10g	USD 250	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Danthron; Chrysazin; Dantron; Antrapurol; Chrysazine;

IUPAC/Chemical Name: 1,8-Dihydroxyanthraquinone

InChi Key: QBPFLULOKWLNNW-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H

SMILES Code: O=C(C1=C2C(O)=CC=C1)C3=CC=CC(O)=C3C2=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 240.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015 May 13;(5):CD003448. doi: 10.1002/14651858.CD003448.pub4. Review. PubMed PMID: 25967924.

2: Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD003448. doi: 10.1002/14651858.CD003448.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;5:CD003448. PubMed PMID: 21249653.

3: Miles CL, Fellowes D, Goodman ML, Wilkinson S. Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD003448. Review. Update in: Cochrane Database Syst Rev. 2011;(1):CD003448. PubMed PMID: 17054172.

4: Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum. 2001 Aug;44(8):1201-9. Review. PubMed PMID: 11535863.

5: Müller L, Kasper P. OTC pharmaceuticals and genotoxicity testing: the paracetamol, anthraquinone, and griseofulvin cases. Arch Toxicol Suppl. 1995;17:312-25. Review. PubMed PMID: 7786168.

6: Gattuso JM, Kamm MA. Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf. 1994 Jan;10(1):47-65. Review. PubMed PMID: 8136086.

7: Dantron (chrysazin; 1,8-dihydroxyanthraquinone). IARC Monogr Eval Carcinog Risks Hum. 1990;50:265-75. Review. Erratum in: IARC Monogr Eval Carcinog Risks Hum 1994;59:257. PubMed PMID: 2292802.

8: Laxatives: replacing danthron. Drug Ther Bull. 1988 Jul 11;26(14):53-6. Review. PubMed PMID: 3042346.

Your view history

Danthron featured